An interventional study of Increased Dialysate Flow and Increased Hemofiltration Flow in Acute Kidney Injuries and Regional Citrate Anticoagulation (RCA), sponsored by Brugmann University Hospital. Completed at 2 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Brugmann University Hospital · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Acute Kidney Injury with a site in Belgium — 5 open to participants now, 8 under way, none of them phase 3. Acute Kidney Injury · Belgium.
Among the 45 studies in Acute Kidney Injury with a site in Belgium, this one is the 19th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2024, is one of 15 with no phase, and was the 45th registered.
1,692 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →5 of the 45 studies in Acute Kidney Injury with a site in Belgium are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Belgium, United States, Argentina and 11 more countries
Ages 18–80
University Hospital, Antwerp · Sites in Belgium
Ages 18+
University Hospital, Antwerp · Sites in Belgium
Ages 18+
University Hospital, Ghent · Sites in Belgium
Ages 18+
University Hospital, Antwerp · Sites in Belgium
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 230 Acute Kidney Injury studies recruiting now, 162 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 100 across 818 interventional studies indexed under Acute Kidney Injury.
Median enrollment 100 across the 31 interventional studies, 307 across the 14 observational. Of the 33 that completed or were terminated, 7 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 45 have an industry lead sponsor. The 10 most frequent:
Brugmann University Hospital is the lead sponsor of 119 studies on the registry; 17 are open to participants now.
Brugmann University Hospital has 1 study filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
3 of the studies in Acute Kidney Injury with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07579390Helsinki University Central HospitalEffects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE) | 2026-12 |
| NCT07207031University Hospital, GhentAcute Kidney Injury - Epidemiology in Intensive Care Unit Patients 2: an International Multicenter Cohort Study | 2026-12-31 |
| NCT07215702AstraZenecaA Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. | 2027-02-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 45 studies in Acute Kidney Injury with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Regional citrate anticoagulation is commonly used during continuous kidney replacement therapy (CKRT) in critically ill patients. Citrate prevents clotting in the extracorporeal circuit by reducing ionized calcium concentrations. However, adequate anticoagulation is not always achieved, and the influence of dialysis and hemofiltration on citrate removal and post-filter ionized calcium remains incompletely understood.
This prospective, single-center, interventional study compares two strategies for increasing extracorporeal clearance in critically ill patients receiving CKRT with regional citrate anticoagulation.
Patients with post-filter ionized calcium concentrations above 0.35 mmol/L two hours after treatment initiation are randomized to either an increase in dialysate flow of 1,000 mL/h or an increase in hemofiltration flow of 1,000 mL/h.
The study evaluates the effects of these two interventions on citrate clearance and post-filter ionized calcium concentrations, with the aim of improving understanding of citrate handling during CKRT.
Regional citrate anticoagulation (RCA) is used during continuous kidney replacement therapy (CKRT) to prevent clotting within the extracorporeal circuit. Its anticoagulant effect depends on the chelation of ionized calcium by citrate. Citrate removal through the extracorporeal circuit may influence both citrate exposure and post-filter ionized calcium concentrations.
The relative effects of increasing dialysate flow and increasing hemofiltration flow on citrate clearance remain insufficiently characterized.
This prospective, single-center, randomized physiological study is conducted in the intensive care unit of Brugmann University Hospital, Brussels, Belgium.
Patients receiving CKRT with RCA undergo an initial two-hour treatment period. Patients whose post-filter ionized calcium concentration remains above 0.35 mmol/L at H2 are eligible for randomization between two treatment adjustments:
Physiological and biochemical measurements are obtained to assess citrate handling and post-filter ionized calcium before and after the treatment adjustment, including measurements at H2 and H4.
The study is designed to compare the physiological effects of the two strategies and to provide evidence for optimizing regional citrate anticoagulation during CKRT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Critically ill patients with acute kidney injury requiring continuous kidney replacement therapy with regional citrate anticoagulation.
Exclusion Criteria:
Patients receiving continuous kidney replacement therapy with regional citrate anticoagulation and presenting a post-filter ionized calcium concentration above 0.35 mmol/L at H2 are randomized to an increase in dialysate flow of 1,000 mL/h. Citrate clearance and post-filter ionized calcium are assessed before and after the intervention, including at H4.
Procedure: Increased Dialysate Flow
Patients receiving continuous kidney replacement therapy with regional citrate anticoagulation and presenting a post-filter ionized calcium concentration above 0.35 mmol/L at H2 are randomized to an increase in hemofiltration flow of 1,000 mL/h. Citrate clearance and post-filter ionized calcium are assessed before and after the intervention, including at H4.
Procedure: Increased Hemofiltration Flow
Increase in dialysate flow rate by 1,000 mL/h at H2 in patients receiving continuous kidney replacement therapy with regional citrate anticoagulation and presenting a post-filter ionized calcium concentration above 0.35 mmol/L.
Increase in hemofiltration flow rate by 1,000 mL/h at H2 in patients receiving continuous kidney replacement therapy with regional citrate anticoagulation and presenting a post-filter ionized calcium concentration above 0.35 mmol/L.
Decrease in Ionized Calcium Across the Hemofilter
Decrease in ionized calcium concentration across the extracorporeal hemofilter, expressed in mmol/L, assessed two hours after the start of continuous kidney replacement therapy (H2, before randomization) and two hours after the assigned treatment adjustment (H4).
Time frame: Two hours after the start of continuous kidney replacement therapy (H2) and two hours after the assigned treatment adjustment (H4)
Achievement of Target Post-Filter Ionized Calcium
Proportion of patients achieving a post-filter ionized calcium concentration of 0.35 mmol/L or lower, assessed at H2 (two hours after the start of continuous kidney replacement therapy).
Time frame: Two hours after the start of continuous kidney replacement therapy (H2)
Achievement of Target Post-Filter Ionized Calcium
Proportion of patients achieving a post-filter ionized calcium concentration of 0.35 mmol/L or lower, assessed at H4 (two hours after the assigned treatment adjustment).
Time frame: Two hours after the assigned treatment adjustment (H4)
Change in Systemic Ionized Calcium Concentration
Change in systemic ionized calcium concentration (mmol/L) between H2 (two hours after the start of continuous kidney replacement therapy) and H4 (two hours after the assigned treatment adjustment) during continuous kidney replacement therapy with regional citrate anticoagulation.
Time frame: Two hours after the start of continuous kidney replacement therapy (H2) and two hours after the assigned treatment adjustment (H4)
Change in Extracorporeal Citrate Clearance
Change in extracorporeal citrate clearance between H2 (two hours after the start of continuous kidney replacement therapy) and H4 (two hours after the assigned treatment adjustment) following an increase in dialysate flow or hemofiltration flow by 1,000 mL/h. Citrate clearance is calculated using citrate concentrations and extracorporeal circuit flow parameters.
Time frame: Two hours after the start of continuous kidney replacement therapy (H2) and two hours after the assigned treatment adjustment (H4)
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2024 to primary completion in Sep 2025, 16 months.
Of 251 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's 16 months is below that.
Counting every sponsor, half of 269 studies reached it within 26 months; a quarter within 12 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brugmann University Hospital →